1. Roche's risdiplam deal a relief for SMA rivals Biogen and Novartis--for now— AstraZeneca targets summer start for COVID-19 antibody trial — Keros Therapeutics raises $96M in upsized IPO — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

2019 financial results

Discussion in 'Kala Pharmaceuticals' started by anonymous, Feb 6, 2020 at 9:43 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I am a drug rep but not at Kala. I do however own some Kala stock. Any info regarding 2019 financial results next week? Did the company hit most RX goals or miss?

    Also I read the thread about no NSM. Is this true or just typical cafepharma negative trolls?

    any real answers is greatly appreciated!
     

  2. anonymous

    anonymous Guest

    I am in same boat as you. I have friends who work at Kala. They say sales were eh.
     
  3. anonymous

    anonymous Guest

    Lol ya ok
     
  4. anonymous

    anonymous Guest

    Its l o t e p r e d n o l........for gods sake nothing earth shattering